Project Grant R01AR083903
Award Date
1/1/25
Completion Date
12/31/30
Dollars Obligated
$378K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research focused on understanding the molecular regulation of growth plate chondrocytes and their role in skeletal patterning. The $221,484 award to The Children's Hospital of Philadelphia Research Institute will fund a 3-year project to: 1) thoroughly define the skeletal phenotypes...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research on the role of mitochondrial respiration and bioenergetic metabolism in the development and differentiation of growth plate chondrocytes. The $459,820 award to The Trustees of the University of Pennsylvania, Clinical Practices of the University of Pennsylvania, will fund a...
This Project Grant award of $1,150,474 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to explore the cellular and molecular mechanisms driving large-scale bone regeneration. The research aims to unravel the intricate events necessary for extensive bone repair by investigating the role of a sentinel-type cell population marked by SOX9 expression in...
This Project Grant award for $144,362 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the critical factors regulating the fate determination of chondrocyte progenitor cells during synovial joint and bone development. The objectives of the study are to determine: 1) the extent to which candidate transcription factors like PITX1 and ATF4...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,938,605 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the Van Andel Research Institute (VAI) to investigate the mechanisms by which the X-linked chromatin modifying enzyme KDM5C regulates female bone mass. The goal is to determine how KDM5C transcriptionally programs genes that control osteoclast differentiation and function, and to assess whether KDM5C...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This $162,500 project grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to generate preliminary data on the relationships between mechanical loading, zinc homeostasis, and bone fracture healing. The award recipient, The Trustees of the University of Pennsylvania, will conduct in vivo studies using a rat femoral osteotomy model to investigate how the...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the mechanisms by which mechanical and hormonal signals interact within bone cells to stimulate bone formation. The $175,948 award, effective June 1, 2025 through May 31, 2030, will be conducted by The General Hospital Corporation, doing business as Massachusetts...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...